Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Bevacizumab Biosimilars Market?

There has been a significant increase in the size of the bevacizumab biosimilars market in the recent past. It is projected to rise from $1.53 billion in 2024 to $1.66 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.2%. Factors such as patent expiration, healthcare cost containment, a rise in cancer cases, market competitiveness, patient access and affordability, and the acceptance of biosimilars contributed to the growth during the historic period.

What Growth Rate Is Forecasted for the Bevacizumab Biosimilars Market by 2029?

In the coming years, the market size for bevacizumab biosimilars is anticipated to experience robust growth, with expectations to reach a market value of $2.27 billion in 2029. This represents a compound annual growth rate (CAGR) of 8.1%. Several factors, such as the growing need for cancer therapies, expertise in biosimilar development, pressures on the healthcare system, regulatory landscape, and biosimilar interchangeability, have all been highlighted as contributing to growth during the forecast period. Key trends to watch throughout the forecast period comprise collaborations and partnerships, advancements in regulatory measures and approval, novel approaches in biosimilar development, strategies for market access, and the management of biosimilar lifecycle.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10848&type=smp

Which Key Companies Are Shaping the Future of the Bevacizumab Biosimilars Market?

Major companies operating in the bevacizumab biosimilars market include Cipla Limited, Reliance lifesciences Pvt. Ltd., Fujifilm Kyowa Kirin Biologics Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Mylan Inc., Daiichi Sankyo Company Limited, Beaconpharma Ltd., Innovent Biologics Inc., STADA Arzneimittel AG, Shanghai Henlius Biotech Inc., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Biocon Ltd., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals LLC, Samsung Bioepis Co. Ltd., Celltrion Inc., Coherus BioSciences Inc., Hetero Drugs Ltd., Apotex Inc., BioXpress Therapeutics SA, mAbxience SA

Which Factors Are Driving Demand in the Bevacizumab Biosimilars Industry?

The anticipated surge in cancer rates is likely to contribute to the expansion of the bevacizumab biosimilar market. The term cancer incidence denotes the count of fresh cancer cases in a specific demographic over a certain timeframe. Bevacizumab, a biologic, obstructs tumor angiogenesis, potentially leading to tumor reduction and inhibiting its growth, and its effectiveness and safety in treating patients with advanced non-small cell lung cancer or metastatic colorectal cancer matches that of reference biologics. To illustrate, The UK’s National Health Service (NHS) reported in October 2024 that there were 346,217 fresh cancer diagnoses in 2022, averaging 948 instances daily. This signifies a surge of 5% as opposed to the 329,664 recorded diagnoses in 2021. There was also a 7% upswing in cancer diagnoses, rising from 167,917 to 180,877 cases in 2022. As such, the escalating incidence of cancer is fuelling the growth of the bevacizumab biosimilars market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10848&type=smp

How Is the Bevacizumab Biosimilars Market Segmented by Several Divisions?

The bevacizumab biosimilars market covered in this report is segmented –

1) By Product: Avastin, Mvasi, Zirabev, Aybintio, Other Products

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Colorectal Cancer, Non-small Cell Lung Cancer, Glioblastoma, Renal Cell Carcinoma, Cervical Cancer, Ovarian Cancer

Subsegments:

1) By Avastin: Original Avastin Product

2) By Mvasi: Mvasi (Amgen Biosimilar)

3) By Zirabev: Zirabev (Pfizer Biosimilar)

4) By Aybintio: Aybintio (Samsung Bioepis Biosimilar)

5) By Other Products: Additional Bevacizumab Biosimilars

What are the Emerging Market Trends Driving the Growth of the Bevacizumab Biosimilars Industry?

A prominent trend observed in the bevacizumab biosimilars market is the emphasis on product innovation. Main players in the market are focusing on developing novel products to solidify their market hold. For example, in May 2022, Viatris and Biocon Biologics, both US-based pharmaceutical companies, introduced a biosimilar named Abevmy (bevacizumab), similar to Roche’s Avastin (bevacizumab). Health Canada has given its approval for the use of Abevmy in four oncology contexts. Comparable to the reference biologic in terms of efficacy, safety, and quality, Abevmy is a humanized monoclonal antibody (MA) derivative that inhibits the biological action of the human vascular endothelial growth factor (VEGF).

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Which Regions Are Driving Growth in the Bevacizumab Biosimilars Market?

North America was the largest region in the bevacizumab biosimilars market in 2024. The regions covered in the bevacizumab biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10848

This Report Delivers Insight On:

1. How big is the bevacizumab biosimilars market, and how is it changing globally?

2. Who are the major companies in the bevacizumab biosimilars market, and how are they performing?

3. What are the key opportunities and risks in the bevacizumab biosimilars market right now?

4. Which products or customer segments are growing the most in the bevacizumab biosimilars market?

5. What factors are helping or slowing down the growth of the bevacizumab biosimilars market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model